Cited by 624Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Paz-Ares, Luis G., de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Pujol, Jean-Louis, Bidoli, Paolo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, Reck, Martin, Corral, Jesús, Melemed, Symantha, John, William, Chouaki, Nadia, Zimmermann, Annamaria H., Visseren-Grul, Carla, Gridelli, Cesare·2013·Journal of Clinical Oncology

DOI 10.1200/jco.2012.47.1102

Open this paper in CoChat — free account

Abstract

PURPOSE: In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data. PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180). Log-rank test compared OS between arms as measured from random assignment (α = .0498). RESULTS: The mean number of maintenance cycles was 7.9 (range, one to 44) for pemetrexed and 5.0 (range, one to 38) for placebo. After 397 deaths (pemetrexed, 71%; placebo, 78%) and a median follow-up of 24.3 months for alive patients (95% CI, 23.2 to 25.1 months), pemetrexed therapy resulted in a statistically significant 22% reduction in the risk of death (HR, 0.78; 95% CI, 0.64 to 0.96; P = .0195; median OS: pemetrexed, 13.9 months; placebo, 11.0 months). Survival on pemetrexed was consistently improved for all patient subgroups, including induction response: complete/partial responders (n = 234) OS HR, 0.81; 95% CI, 0.59 to 1.11 and stable disease (n = 285) OS HR, 0.76; 95% CI, 0.57 to 1.01). Postdiscontinuation therapy use was similar: pemetrexed, 64%; placebo, 72%. No new safety findings emerged. Drug-related grade 3 to 4 anemia, fatigue, and neutropenia were significantly higher in pemetrexed-treated patients. CONCLUSION: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexed-cisplatin induction therapy.

Integrity signals

Registry

Crossref · 10.1200/jco.2012.47.1102

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
AJCC Cancer Staging Manual
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 6,011
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Self-citation
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 722
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610
Self-citation
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
Fidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova‐Kazmierski, M. K., Treat, J., Obasaju, C. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1405 · Cited by 418
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D’Addario, G., Früh, M., Reck, M., Baumann, P., Klepetko, W., & Felip, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq189 · Cited by 324
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
Brodowicz, T., Krzakowski, M. J., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., Ciuleanu, T., Čučević, B., Gyurkovits, K., Ulsperger, E., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.006 · Cited by 320
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Temin, S., Aliff, T. B., Baker, S., Brahmer, J. R., Johnson, D. H., Laskin, J. L., Masters, G. A., Milton, D. T., Nordquist, L. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2774 · Cited by 290
Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
Scagliotti, G. V., Brodowicz, T., Shepherd, F. A., Zielinski, C. C., Vansteenkiste, J., Manegold, C., Simms, L., Fossella, F. V., Sugarman, K. P., & Belani, C. P. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f7c6d4 · Cited by 252
Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Pérol, M., CHOUAID, C., Pérol, D., Barlési, F., Gervais, R., Westeel, V., Créquit, J., Léna, H., Vergnenégre, A., Zalcman, G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9782 · Cited by 231
Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
Soon, Y. Y., Stockler, M. R., Askie, L. M., & Boyer, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4522 · Cited by 197
Analysis of Binary Data.
Cox, D. R., & Snell, E. J. (1990) · Biometrics · doi:10.2307/2531476 · Cited by 129
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
Coudert, B. P., Ciuleanu, T., Park, K., Wu, Y.-L. L. C., Giaccone, G., Brugger, W., Gopalakrishna, P., & Cappuzzo, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr125 · Cited by 104
Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).
Belani, C. P., Waterhouse, D. M., Ghazal, H., Ramalingam, S. S., Bordoni, R. E., Greenberg, R. H., Levine, R. M., Waples, J. M., Jiang, Y., & Reznikoff, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7506 · Cited by 98
Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Fidias, P. M., & Novello, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7074 · Cited by 67
Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Gridelli, C., de Marinis, F., Pujol, J.-L., Reck, M., Ramlau, R., Parente, B., Pieters, T., Middleton, G., Corral, J., Winfree, K. B., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318267cf84 · Cited by 58
Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis
Behera, M., Owonikoko, T. K., Chen, Z., Kono, S. A., Khuri, F. R., Belani, C. P., & Ramalingam, S. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.019 · Cited by 56
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
Gridelli, C., Maione, P., Rossi, A., Ferrara, M. L., Bareschino, M. A., Schettino, C., Sacco, P. C., & Ciardiello, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0152 · Cited by 51
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg, M. B., & Edelman, M. J. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0020-6 · Cited by 41
Duration of First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Less Is More in the Era of Effective Subsequent Therapies
Socinski, M. A., & Stinchcombe, T. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4015 · Cited by 39
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
Paz-Ares, L. G., Altuǧ, S., Vaury, A. T., Jaime, J. C., Russo, F. P., & Visseren‐Grul, C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-85 · Cited by 35
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial
Belani, C. P., Wu, Y.-L. L. C., Chen, Y.-M., Kim, J.-H., Yang, S. L., Zhang, L., Peterson, P. M., & Orlando, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823d4f9d · Cited by 28

Flagged first, then by citations

Research works printed but not linked: 1

Ciuleanu T, 2008, Ann Oncol, 19, viii98

Sorted by citations

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L. L. C., & Paz-Ares, L. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,430
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Lung cancer
Thai, A. A., Solomon, B., Sequist, L. V. D., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,753
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274

See all 624

PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba7507 · Cited by 19
PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Reck, M., Paz-Ares, L. G., de Marinis, F., Molinier, O., Sahoo, T. P., Laack, E., John, W. J., Zimmermann, A. H., Visseren‐Grul, C., & Gridelli, C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000076 · Cited by 16
Littérature commentée décembre 2014
(2014) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.10.002
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Pujol, J.-L., Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Bidoli, P., Corral, J., Antonio, B. S., Chouaki, N., John, W. J., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.007 · Cited by 39
PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).
Paz-Ares, L. G., Marinis, F. D., Dediu, M., Thomas, M., Pujol, J., Bidoli, P., Molinier, O., Sahoo, T.-P., Laack, E., Reck, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra7510 · Cited by 19

See all

Authors: Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., Corral, J., Melemed, S., John, W., Chouaki, N., Zimmermann, A. H., Visseren-Grul, C., & Gridelli, C.
Affiliations: Heidelberg University (DE)
Luis Paz-Ares and Jesús Corral, University Hospital Virgen del Rocío, Seville, Spain; Filippo de Marinis, San Camillo-Forlanini Hospital, Rome; Paolo Bidoli, S. Gerardo Hospital, Monza; Cesare Gridelli, San Giuseppe Moscati Hospital, Avellino, Italy; Mircea Dediu, Institute of Oncology Bucharest, Bucharest, Romania; Michael Thomas, University of Heidelberg, Heidelberg; Eckart Laack, University Medical Center Hamburg-Eppendorf, Hamburg; Martin Reck, Hospital Grosshansdorf, Grosshansdorf, Germany; Jean...
ORCID: Paz-Ares, Luis G.
Dediu, Mircea
Thomas, Michael
Pujol, Jean-Louis
Molinier, Olivier
Reck, Martin
Gridelli, Cesare
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2013-08-10
Volume: 31
Issue: 23
Pages: 2895-2902
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2012.47.1102
OpenAlex: W2167191456
Cited by: 624
References: 32
Citations by year: 2026: 10 · 2025: 18 · 2024: 23 · 2023: 24 · 2022: 31 · 2021: 47 · 2020: 52 · 2019: 53 · 2018: 72 · 2017: 63 · 2016: 66 · 2015: 76 · 2014: 72 · 2013: 13
FWCI: 61.17
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Funders: Eli Lilly and Company
American Society of Clinical Oncology
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: maintenance therapy, pemetrexed, cisplatin, advanced nonsquamous non-small cell lung cancer, overall survival, induction chemotherapy, treatment safety, subgroup analysis, disease progression, prognostic factors, prognostic score, treatment-related adverse events, neutropenia, febrile neutropenia, thrombocytopenia
MeSH terms: Pemetrexed, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Double-Blind Method, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Remission Induction, Survival Analysis, Treatment Outcome, Disease-Free Survival, Induction Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks